Valsartan

證據等級: L5

預測適應症: 7 個

Valsartan: From Hypertension to Malignant Hypertensive Renal Disease

One-Sentence Summary

Valsartan is a well-established angiotensin II receptor blocker (ARB); this evidence pack does not include structured data on its originally approved indications, but ARBs are broadly used for hypertension and heart failure. The TxGNN model predicts it may be effective for Malignant Hypertensive Renal Disease, but currently only 0 clinical trials and 1 indirect publication (studying a different drug, avosentan) support this specific direction.

Quick Overview

Item	Content
Original Indication	Not available in evidence pack (Valsartan is a class-recognized ARB commonly indicated for hypertension/heart failure; no structured `original_indications` or license text was provided)
Predicted New Indication	Malignant Hypertensive Renal Disease
TxGNN Prediction Score	99.97%
Evidence Level	L4
Market Status	Not marketed (未上市)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for this record (original_moa: [Data Gap]). Based on known pharmacology, valsartan is an angiotensin II type 1 (AT1) receptor blocker that suppresses the renin-angiotensin-aldosterone system (RAAS), lowering glomerular capillary pressure and reducing proteinuria — a mechanism broadly associated with renal protection in hypertensive nephropathy.

Malignant hypertension with renal involvement is characterized by markedly elevated angiotensin II activity and RAAS-driven vascular/glomerular injury, making RAAS blockade mechanistically plausible. However, malignant hypertension is a hypertensive emergency requiring rapid blood pressure control; oral ARBs have a slow onset of action and are not first-line for the acute phase, limiting direct applicability.

Importantly, the single literature citation supporting this prediction (PMID 24368192) studies avosentan, an endothelin receptor antagonist, not valsartan — it only indirectly supports the general concept that blocking vasoactive/pressor pathways can protect against hypertensive nephropathy in an animal model. No valsartan-specific clinical or preclinical data were retrieved for this indication, so the mechanistic link should be regarded as a class-level hypothesis rather than drug-specific evidence.

Note: This evidence pack contains 7 TxGNN-predicted indications for valsartan. Two are flagged at "Research Question" stage — this one (rank 1, L4, driven mainly by TxGNN score) and "chronic pulmonary heart disease" (rank 6, L2, supported by multiple completed Phase 3/4 RCTs of sacubitril/valsartan in HFrEF with right-ventricular/pulmonary comorbidity). The rank 6 candidate has a materially stronger clinical evidence base and may warrant separate evaluation.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
24368192	2014	Preclinical/Review	Pharmacological Research	Endothelin receptor antagonist (avosentan) — not valsartan — showed renal protection in a hypertensive nephropathy rat model (double transgenic rats overexpressing renin/angiotensinogen) at doses avoiding fluid retention. Supports the general RAAS/vasoactive-pathway nephroprotection concept but provides no direct valsartan data.

Germany Market Information

Valsartan currently has no recorded marketing authorization in this dataset (market status: Not marketed, 0 licenses).

Safety Considerations

Please refer to the package insert for safety information.

(Note: A blocking data gap exists — TFDA-equivalent product label warnings/contraindications for valsartan could not be retrieved (DG001), which currently prevents a formal S1 safety assessment.)

Conclusion and Next Steps

Decision: Hold

Rationale: The predicted indication is supported only by a TxGNN score with no clinical trials and a single piece of indirect, non-valsartan-specific literature (L4 evidence). Combined with the drug's "Not marketed" status and a blocking gap in label-level safety data, there is insufficient evidence to proceed toward a safety review at this time.

To proceed, the following is needed:

Product label / official safety warnings and contraindications for valsartan (DG001, Blocking — required before S1 safety evaluation)
Detailed mechanism of action documentation (DG002)
Direct preclinical or clinical evidence using valsartan itself (not endothelin antagonists) for hypertensive nephropathy or malignant hypertension
Consider a separate evaluation track for the "chronic pulmonary heart disease" candidate (rank 6), which has notably stronger evidence (L2, multiple completed Phase 3/4 RCTs of sacubitril/valsartan)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.